A phase III, Randomized, two armed, parallel, double blind Controlled non inferiority clinical Trial of Tinapeg(Produced by AryaTinaGene.) versus Neulastim for Preventing Chemotherapy induced Febrile Neutropenia in breast Cancer Patients

Trial Profile

A phase III, Randomized, two armed, parallel, double blind Controlled non inferiority clinical Trial of Tinapeg(Produced by AryaTinaGene.) versus Neulastim for Preventing Chemotherapy induced Febrile Neutropenia in breast Cancer Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Chemotherapy-induced damage; Febrile neutropenia
  • Focus Registrational; Therapeutic Use
  • Sponsors AryaTinaGene Biopharmaceuticals
  • Most Recent Events

    • 22 Feb 2018 Status changed from recruiting to completed.
    • 22 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top